Vera Therapeutics Inc banner

Vera Therapeutics Inc
NASDAQ:VERA

Watchlist Manager
Vera Therapeutics Inc Logo
Vera Therapeutics Inc
NASDAQ:VERA
Watchlist
Price: 40.33 USD 0.82%
Market Cap: $2.9B

Multiples-Based Value

The Multiples-Based Value of one VERA stock under the Base Case scenario is 46.82 USD. Compared to the current market price of 40.33 USD, Vera Therapeutics Inc is Undervalued by 14%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VERA Multiples-Based Value
Base Case
46.82 USD
Undervaluation 14%
Multiples-Based Value
Price $40.33
Worst Case
Base Case
Best Case

Multiples Across Competitors

VERA Competitors Multiples
Vera Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Vera Therapeutics Inc
NASDAQ:VERA
2.9B USD 0 -9.6 -7.1 -7.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
374.1B USD 6.2 90.1 14.9 20.7
US
Amgen Inc
NASDAQ:AMGN
188.5B USD 5.2 25 14.4 14.4
US
Gilead Sciences Inc
NASDAQ:GILD
175.7B USD 6 20.8 13 16
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.8B USD 9.4 28.4 21.4 22.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82B USD 5.6 18 13.4 15.3
NL
argenx SE
XBRU:ARGX
41.5B EUR 11.8 37.9 40.9 41.8
AU
CSL Ltd
ASX:CSL
68.5B AUD 3 33.2 11.2 14
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
US
Vera Therapeutics Inc
NASDAQ:VERA
Average P/S: 3 369 303.1
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.2
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.2
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
6
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.4
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
10%
0.6
NL
argenx SE
XBRU:ARGX
11.8
28%
0.4
AU
CSL Ltd
ASX:CSL
3
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Vera Therapeutics Inc
NASDAQ:VERA
Average P/E: 36.2
Negative Multiple: -9.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
90.1
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
25
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.8
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.4
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
13%
1.4
NL
argenx SE
XBRU:ARGX
37.9
32%
1.2
AU
CSL Ltd
ASX:CSL
33.2
10%
3.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Vera Therapeutics Inc
NASDAQ:VERA
Average EV/EBITDA: 18.5
Negative Multiple: -7.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.9
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
13
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.4
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.4
18%
0.7
NL
argenx SE
XBRU:ARGX
40.9
50%
0.8
AU
CSL Ltd
ASX:CSL
11.2
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Vera Therapeutics Inc
NASDAQ:VERA
Average EV/EBIT: 20.7
Negative Multiple: -7.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.7
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.4
3%
4.8
US
Gilead Sciences Inc
NASDAQ:GILD
16
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.3
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
23%
0.7
NL
argenx SE
XBRU:ARGX
41.8
51%
0.8
AU
CSL Ltd
ASX:CSL
14
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett